TY - JOUR
T1 - Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma
T2 - A Multidisciplinary Approach
AU - Cho, May T.
AU - Gholami, Sepideh
AU - Gui, Dorina
AU - Tejaswi, Sooraj L.
AU - Fananapazir, Ghaneh
AU - Abi-Jaoudeh, Nadine
AU - Jutric, Zeljka
AU - Samarasena, Jason B.
AU - Li, Xiaodong
AU - Valerin, Jennifer B.
AU - Mercer, Jacob
AU - Dayyani, Farshid
N1 - Funding Information:
This research received no external funding; financial support for the medical and editorial assistance was provided by QED Therapeutics, Inc. San Francisco, CA, USA and Helsinn Therapeutics (U.S.), Inc. Iselin, NJ, USA.
Funding Information:
Funding: This research received no external funding; financial support for the medical and editorial assistance was provided by QED Therapeutics, Inc. San Francisco, CA, USA and Helsinn Therapeutics (U.S.), Inc. Iselin, NJ, USA.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Cholangiocarcinoma (CCA) is a heterogenous group of malignancies originating in the biliary tree, and associated with poor prognosis. Until recently, treatment options have been limited to surgical resection, liver-directed therapies, and chemotherapy. Identification of actionable genomic alterations with biomarker testing has revolutionized the treatment paradigm for these patients. However, several challenges exist to the seamless adoption of precision medicine in patients with CCA, relating to a lack of awareness of the importance of biomarker testing, hurdles in tissue acquisition, and ineffective collaboration among the multidisciplinary team (MDT). To identify gaps in standard practices and define best practices, multidisciplinary hepatobiliary teams from the University of California (UC) Davis and UC Irvine were convened; discussions of the meeting, including optimal approaches to tissue acquisition for diagnosis and biomarker testing, communication among academic and community healthcare teams, and physician education regarding biomarker testing, are summarized in this review.
AB - Cholangiocarcinoma (CCA) is a heterogenous group of malignancies originating in the biliary tree, and associated with poor prognosis. Until recently, treatment options have been limited to surgical resection, liver-directed therapies, and chemotherapy. Identification of actionable genomic alterations with biomarker testing has revolutionized the treatment paradigm for these patients. However, several challenges exist to the seamless adoption of precision medicine in patients with CCA, relating to a lack of awareness of the importance of biomarker testing, hurdles in tissue acquisition, and ineffective collaboration among the multidisciplinary team (MDT). To identify gaps in standard practices and define best practices, multidisciplinary hepatobiliary teams from the University of California (UC) Davis and UC Irvine were convened; discussions of the meeting, including optimal approaches to tissue acquisition for diagnosis and biomarker testing, communication among academic and community healthcare teams, and physician education regarding biomarker testing, are summarized in this review.
KW - Best practices
KW - Biomarker testing
KW - Challenges
KW - Cholangiocarcinoma
KW - Genomic alterations
KW - Multidisciplinary
KW - Next-generation sequencing
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85122873117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122873117&partnerID=8YFLogxK
U2 - 10.3390/cancers14020392
DO - 10.3390/cancers14020392
M3 - Review article
AN - SCOPUS:85122873117
VL - 14
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 2
M1 - 392
ER -